Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.22 BRL | -1.87% | -1.31% | +14.55% |
06-14 | Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto | DJ |
06-14 | Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer | MT |
Evolution of the average Target Price on Amgen Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Amgen Inc.
RBC Capital Markets | |
HSBC | |
Redburn Atlantic | |
Mizuho Securities | |
UBS | |
Deutsche Bank Securities | |
William Blair & Co. | |
Leerink Partners | |
Barclays | |
Morgan Stanley | |
BMO Capital | |
Goldman Sachs | |
TD Cowen | |
Oppenheimer | |
Baird | |
Daiwa Securities | |
Truist Securities | |
Argus | |
Jefferies & Co. | |
Credit Suisse | |
DA Davidson | |
Piper Sandler | |
Wells Fargo Securities | |
SVB Securities LLC | |
Cowen | |
Atlantic Equities | |
BofA Securities | |
SVB Leerink | |
JPMORGAN | Cory Kasimov |
RBC | Kennen Mackay |
EPS Revisions
- Stock Market
- Equities
- AMGN Stock
- AMGN34 Stock
- Consensus Amgen Inc.